Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors

NCT01122264 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01122264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01122264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2010
Completion date
June 30, 2011
Enrollment
770 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

erectile dysfunction